Vaccine, Johnson & Johnson: 'Neutralising antibody responses stable 8 months after immunisation'
Covid neutralizing antibodies, J&J: “A booster dose of Johnson & Johnson’s COVID-19 vaccine generated a rapid and robust increase in antibodies”
Johnson & Johnson announced data that “support the use of its Covid-19 vaccine as a booster for people who had previously been given Johnson & Johnson’s single-dose vaccine.
In July, the company reported interim Phase 1/2a data published in the New England Journal of Medicine that showed the neutralising antibody responses generated by Johnson & Johnson’s Covid-19 vaccine remained robust and stable for up to eight months after immunisation,” the company said.
J&J’s note on Covid-neutralising antibodies states
In anticipation of the potential need for recalls,” the company continues, “a Phase 1/2a study and a Phase 2 study were conducted in individuals who had previously received its vaccine.
Interim data from these studies show that a booster dose of Johnson & Johnson’s COVID-19 vaccine generated a rapid and robust nine-fold increase in antibodies compared to 28 days after the single-dose primary vaccination.
Significant increases in antibody responses were observed in participants aged 18-55 years, and in those aged 65 years and older who received a reduced booster dose.
The study summaries were presented to medRxiv on 24 August.”
“We have ascertained that a single dose of our Covid-19 vaccine generates robust immune responses that are long-lasting and persistent for eight months.
With these data, we also see that a booster dose of Johnson & Johnson’s Covid-19 vaccine further increases antibody responses among study participants who had previously received our vaccine,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, Johnson & Johnson.
We look forward to meeting with public health officials to discuss a potential strategy for our Johnson & Johnson COVID-19 vaccine for a booster shot at eight months or more after single-dose primary vaccination.
The company, the statement concluded, “is in contact with the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and other health authorities regarding the administration of Johnson & Johnson’s COVID-19 vaccine.
Neutralising antibodies, Johnson & Johnson continues to generate and carefully evaluate data from ongoing studies and real-world evidence from its COVID-19 vaccine
The two clinical trials (VAC31518COV1001 and VAC31518COV2001) were funded in part with federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), under Other Transaction Authority (“OTA”) Agreement No. HHSO100201700018C.”